Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease.

Wang S, Kojima K, Mobley JA, West AB.

EBioMedicine. 2019 Jul;45:351-361. doi: 10.1016/j.ebiom.2019.06.021. Epub 2019 Jun 20.

2.

A Competency-Guided Veterinary Curriculum Review Process.

Varnum AT, West AB, Hendrickson DA.

J Vet Med Educ. 2019 Jun 13:1-11. doi: 10.3138/jvme.1217-183r1. [Epub ahead of print]

PMID:
31194636
3.

Caught in the act: LRRK2 in exosomes.

Wang S, West AB.

Biochem Soc Trans. 2019 Apr 30;47(2):663-670. doi: 10.1042/BST20180467. Epub 2019 Mar 5. Review.

PMID:
30837321
4.

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Cresto N, Gardier C, Gubinelli F, Gaillard MC, Liot G, West AB, Brouillet E.

Eur J Neurosci. 2019 Feb;49(3):339-363. doi: 10.1111/ejn.14182. Epub 2018 Oct 24.

PMID:
30269383
5.

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Kelly K, Wang S, Boddu R, Liu Z, Moukha-Chafiq O, Augelli-Szafran C, West AB.

Exp Neurol. 2018 Nov;309:1-13. doi: 10.1016/j.expneurol.2018.07.012. Epub 2018 Jul 24.

6.

Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies.

Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D, Scott HJ, Underwood RN, Liu Z, Volpicelli-Daley LA, West AB.

J Comp Neurol. 2018 Aug 15;526(12):1978-1990. doi: 10.1002/cne.24468.

7.

LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network.

Liu Z, Bryant N, Kumaran R, Beilina A, Abeliovich A, Cookson MR, West AB.

Hum Mol Genet. 2018 Jan 15;27(2):385-395. doi: 10.1093/hmg/ddx410.

8.

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.

Wang S, Liu Z, Ye T, Mabrouk OS, Maltbie T, Aasly J, West AB.

Acta Neuropathol Commun. 2017 Nov 22;5(1):86. doi: 10.1186/s40478-017-0492-y.

9.

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration.

Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, Jurkuvenaite A, West AB.

Acta Neuropathol Commun. 2017 Nov 21;5(1):85. doi: 10.1186/s40478-017-0494-9.

10.

Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.

Abdelmotilib H, West AB.

Genome Med. 2017 Oct 19;9(1):88. doi: 10.1186/s13073-017-0483-4.

11.

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.

Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA.

Mol Ther Nucleic Acids. 2017 Sep 15;8:508-519. doi: 10.1016/j.omtn.2017.08.002. Epub 2017 Aug 10.

12.

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.

West AB.

Exp Neurol. 2017 Dec;298(Pt B):236-245. doi: 10.1016/j.expneurol.2017.07.019. Epub 2017 Jul 29. Review.

13.

LRRK2 levels in immune cells are increased in Parkinson's disease.

Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, Grigoryan N, Factor SA, West AB, Boss JM, Tansey MG.

NPJ Parkinsons Dis. 2017 Mar 28;3:11. doi: 10.1038/s41531-017-0010-8. eCollection 2017.

14.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

15.

Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Histopathologic Features and Clinical Correlations.

Ta R, Celli R, West AB.

Case Rep Pathol. 2017;2017:1936282. doi: 10.1155/2017/1936282. Epub 2017 Apr 27.

16.

Biochemical characterization of purified mammalian ARL13B protein indicates that it is an atypical GTPase and ARL3 guanine nucleotide exchange factor (GEF).

Ivanova AA, Caspary T, Seyfried NT, Duong DM, West AB, Liu Z, Kahn RA.

J Biol Chem. 2017 Jun 30;292(26):11091-11108. doi: 10.1074/jbc.M117.784025. Epub 2017 May 9.

17.

Exaggerated CpH methylation in the autism-affected brain.

Ellis SE, Gupta S, Moes A, West AB, Arking DE.

Mol Autism. 2017 Feb 17;8:6. doi: 10.1186/s13229-017-0119-y. eCollection 2017.

18.

The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.

Liu Z, West AB.

Biochim Biophys Acta Proteins Proteom. 2017 Mar;1865(3):274-280. doi: 10.1016/j.bbapap.2016.12.001. Epub 2016 Dec 8.

19.

G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.

Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood AJ, Unni VK, Hirst WD, Yue Z, Zhao HT, Fraser K, Kennedy RE, West AB.

J Neurosci. 2016 Jul 13;36(28):7415-27. doi: 10.1523/JNEUROSCI.3642-15.2016.

20.

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.

Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N; Parkinson's Disease Biomarker Program Consortium, West AB.

Mov Disord. 2016 Oct;31(10):1543-1550. doi: 10.1002/mds.26686.

21.

Transcriptome analysis of cortical tissue reveals shared sets of downregulated genes in autism and schizophrenia.

Ellis SE, Panitch R, West AB, Arking DE.

Transl Psychiatry. 2016 May 24;6:e817. doi: 10.1038/tp.2016.87.

22.

Identification of bona-fide LRRK2 kinase substrates.

West AB, Cookson MR.

Mov Disord. 2016 Aug;31(8):1140-1. doi: 10.1002/mds.26647. Epub 2016 Apr 29. No abstract available.

23.

Evaluating Intestinal Infections: A Systematic Approach.

Barbieri A, West AB.

Adv Anat Pathol. 2016 May;23(3):135-43. doi: 10.1097/PAP.0000000000000111. Review.

PMID:
27058242
24.

Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.

Fraser KB, Moehle MS, Alcalay RN, West AB; LRRK2 Cohort Consortium.

Neurology. 2016 Mar 15;86(11):994-9. doi: 10.1212/WNL.0000000000002436. Epub 2016 Feb 10.

25.

Focal hepatic glycogenosis associated with metastatic insulinoma presenting as mass lesions.

Vyas M, Zhang X, Morrow JS, Jain D, Salem RR, West AB.

Pathol Res Pract. 2016 Jan;212(1):59-62. doi: 10.1016/j.prp.2015.11.006. Epub 2015 Nov 26.

PMID:
26627264
26.

14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Lavalley NJ, Slone SR, Ding H, West AB, Yacoubian TA.

Hum Mol Genet. 2016 Jan 1;25(1):109-22. doi: 10.1093/hmg/ddv453. Epub 2015 Nov 5.

27.

LRRK2 autophosphorylation enhances its GTPase activity.

Liu Z, Mobley JA, DeLucas LJ, Kahn RA, West AB.

FASEB J. 2016 Jan;30(1):336-47. doi: 10.1096/fj.15-277095. Epub 2015 Sep 22.

28.

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Daher JP, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB.

J Biol Chem. 2015 Aug 7;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub 2015 Jun 15.

29.

The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Moehle MS, Daher JP, Hull TD, Boddu R, Abdelmotilib HA, Mobley J, Kannarkat GT, Tansey MG, West AB.

Hum Mol Genet. 2015 Aug 1;24(15):4250-67. doi: 10.1093/hmg/ddv157. Epub 2015 Apr 29.

30.

Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.

Boddu R, Hull TD, Bolisetty S, Hu X, Moehle MS, Daher JP, Kamal AI, Joseph R, George JF, Agarwal A, Curtis LM, West AB.

Hum Mol Genet. 2015 Jul 15;24(14):4078-93. doi: 10.1093/hmg/ddv147. Epub 2015 Apr 22.

31.

Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism.

Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, Arking DE.

Nat Commun. 2014 Dec 10;5:5748. doi: 10.1038/ncomms6748.

32.

M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

Moehle MS, West AB.

Neuroscience. 2015 Aug 27;302:59-73. doi: 10.1016/j.neuroscience.2014.11.018. Epub 2014 Nov 25. Review.

33.

Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.

West AB.

Mov Disord. 2015 Feb;30(2):180-9. doi: 10.1002/mds.26075. Epub 2014 Dec 1. Review.

34.

PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.

Lucas EK, Dougherty SE, McMeekin LJ, Reid CS, Dobrunz LE, West AB, Hablitz JJ, Cowell RM.

J Neurosci. 2014 Oct 22;34(43):14375-87. doi: 10.1523/JNEUROSCI.1222-14.2014.

35.

Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.

Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM.

Mol Biol Cell. 2014 Dec 15;25(25):4010-23. doi: 10.1091/mbc.E14-02-0741. Epub 2014 Oct 8.

36.

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.

Liu Z, Galemmo RA Jr, Fraser KB, Moehle MS, Sen S, Volpicelli-Daley LA, DeLucas LJ, Ross LJ, Valiyaveettil J, Moukha-Chafiq O, Pathak AK, Ananthan S, Kezar H, White EL, Gupta V, Maddry JA, Suto MJ, West AB.

J Biol Chem. 2014 Nov 21;289(47):32937-51. doi: 10.1074/jbc.M114.602318. Epub 2014 Sep 16.

37.

Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.

Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9289-94. doi: 10.1073/pnas.1403215111. Epub 2014 Jun 9.

38.

Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

West AB, Cowell RM, Daher JP, Moehle MS, Hinkle KM, Melrose HL, Standaert DG, Volpicelli-Daley LA.

J Comp Neurol. 2014 Aug 1;522(11):2465-80. doi: 10.1002/cne.23583. Epub 2014 Apr 12.

39.

RNA-Seq optimization with eQTL gold standards.

Ellis SE, Gupta S, Ashar FN, Bader JS, West AB, Arking DE.

BMC Genomics. 2013 Dec 17;14:892. doi: 10.1186/1471-2164-14-892.

40.

Diet and lifestyle factors and risk of subtypes of esophageal and gastric cancers: classification tree analysis.

Navarro Silvera SA, Mayne ST, Gammon MD, Vaughan TL, Chow WH, Dubin JA, Dubrow R, Stanford JL, West AB, Rotterdam H, Blot WJ, Risch HA.

Ann Epidemiol. 2014 Jan;24(1):50-7. doi: 10.1016/j.annepidem.2013.10.009. Epub 2013 Oct 18.

41.

Defining the contribution of CNTNAP2 to autism susceptibility.

Sampath S, Bhat S, Gupta S, O'Connor A, West AB, Arking DE, Chakravarti A.

PLoS One. 2013 Oct 17;8(10):e77906. doi: 10.1371/journal.pone.0077906. eCollection 2013.

42.

Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.

Dougherty SE, Hollimon JJ, McMeekin LJ, Bohannon AS, West AB, Lesort M, Hablitz JJ, Cowell RM.

Neurobiol Dis. 2014 Feb;62:160-71. doi: 10.1016/j.nbd.2013.10.002. Epub 2013 Oct 11.

43.

LRRK2 secretion in exosomes is regulated by 14-3-3.

Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, Yacoubian TA, Cowell RM, Dokland T, Ye T, Chen D, Siegal GP, Galemmo RA, Tsika E, Moore DJ, Standaert DG, Kojima K, Mobley JA, West AB.

Hum Mol Genet. 2013 Dec 15;22(24):4988-5000. doi: 10.1093/hmg/ddt346. Epub 2013 Jul 25.

44.

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL.

Biochem J. 2013 Jul 1;453(1):101-13. doi: 10.1042/BJ20121742.

45.

Aortoatrial fistula.

Odaro E, Jain M, Horne M, Van Dyke A, West AB, Manthous CA, Zarich S.

Am J Respir Crit Care Med. 2013 Mar 1;187(5):e9. doi: 10.1164/rccm.201204-0727IM. No abstract available.

PMID:
23457370
46.

Systematic review of sonographic findings of placental mesenchymal dysplasia and subsequent pregnancy outcome.

Nayeri UA, West AB, Grossetta Nardini HK, Copel JA, Sfakianaki AK.

Ultrasound Obstet Gynecol. 2013 Apr;41(4):366-74. doi: 10.1002/uog.12359. Review.

47.

Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.

Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, Glauser L, West AB, Bandopadhyay R, Moore DJ.

PLoS One. 2012;7(10):e47784. doi: 10.1371/journal.pone.0047784. Epub 2012 Oct 17.

48.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

49.

LRRK2 inhibition attenuates microglial inflammatory responses.

Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB.

J Neurosci. 2012 Feb 1;32(5):1602-11. doi: 10.1523/JNEUROSCI.5601-11.2012.

50.

Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.

Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB.

J Mol Biol. 2011 Sep 9;412(1):94-110. doi: 10.1016/j.jmb.2011.07.033. Epub 2011 Jul 22.

Supplemental Content

Support Center